Atlantic Bridge

Atlantic Bridge is a Dublin-based deep tech growth equity firm with offices across Europe, the United States, and Asia. Founded in 2004, the firm has built a distinctive practice at the intersection of deep technology investing and university spinout commercialization, anchored by its University Bridge Fund, which works with leading research institutions to translate academic intellectual property into venture-scale companies.

In healthcare, Atlantic Bridge focuses on AI/ML in healthcare, deep tech, and medical devices, with an emphasis on companies whose technical foundations come from rigorous academic research. The firm is particularly comfortable with categories that combine hardware, software, and complex algorithms, and it has built a portfolio that reflects its willingness to engage with technical risk that more generalist investors avoid. AI is central to the thesis, particularly in applications where it provides genuine technical advantage rather than incremental wrapper functionality.

Atlantic Bridge invests at Seed, Series A, and Series B with check sizes of $1M to $5M from its earlier-stage strategies, with growth equity capital available for later rounds. Geographic focus spans Europe, North America, and Asia, with notable activity in Ireland, the UK, and the broader European deep tech ecosystem. The University Bridge Fund specifically partners with academic institutions to commercialize research, providing both capital and operational support to spinouts at their earliest stages.

The team brings investing, operating, and academic backgrounds, with partners who have built and exited deep tech companies. The firm’s relationships with research institutions, including universities across Ireland, the UK, and continental Europe, give it unusual deal flow into early-stage spinouts and the technical credibility to evaluate them properly. Diligence processes include substantive technical assessment alongside conventional commercial diligence.

Atlantic Bridge’s working approach is patient, technically engaged, and oriented toward building category-defining deep tech companies. Portfolio founders describe partners who are comfortable with the longer development timelines typical of deep tech and who bring relationships across enterprise customers, strategic acquirers, and follow-on investors that can accelerate scale. For founders coming out of academic research, the University Bridge Fund offers a particularly relevant on-ramp, including support on company formation, IP licensing, and early team building. Reporting expectations are professional and aligned with the longer arc of deep tech development, with milestone-based engagement that recognizes the realities of technical and clinical development cycles. The firm will not be the right fit for founders looking for purely commercial software bets without a meaningful technical moat, but for healthcare and life sciences founders whose work depends on advanced algorithms, novel hardware, or proprietary data infrastructure derived from research environments, Atlantic Bridge represents one of the more thoughtful European deep tech specialists currently operating, with a global perspective and a network that supports cross-border scaling.